The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Tanas A.S.
Research Centre for Medical Genetics
Strelnikov V.V.
Research Centre for Medical Genetics
New possibilities in the treatment of Stargardt disease
Journal: Russian Annals of Ophthalmology. 2020;136(4): 333‑343
Views: 13285
Downloaded: 382
To cite this article:
Zhorzholadze NV, Sheremet NL, Tanas AS, Strelnikov VV. New possibilities in the treatment of Stargardt disease. Russian Annals of Ophthalmology.
2020;136(4):333‑343. (In Russ.)
https://doi.org/10.17116/oftalma2020136042333
Stargardt disease is a hereditary retinal dystrophy associated with mutations in the ABCA4 gene. Currently, no etiopathogenetic drugs nor treatment methods for Stargardt disease have completely passed clinical trials. The review summarizes experimental and clinical studies of drugs aimed at reducing the accumulation of vitamin A dimers, lipofuscin, complement inhibition and RPE regeneration by stem cell transplantation, as well as gene therapy studies with intravitreal vector injection of the ABCA4 functional gene.
Keywords:
Authors:
Tanas A.S.
Research Centre for Medical Genetics
Strelnikov V.V.
Research Centre for Medical Genetics
Received:
12.05.2020
Accepted:
17.06.2020
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.